AmBisome®

1-Empirical therapy 2-Systemic fungal infections: Aspergillus Candida Cryptococcus 3-Cryptococcal meningitis in HIV infected patients (1- Empirical therapy for presumed fungal infection in febrile neutropenic patients 2- Treatment of Cryptococcal Meningitis in HIV-infected patients 3- Treatment of Aspergillus species, Candida species and/or Cryptococcus species infections refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate 4- Treatment of visceral leishmaniasis; in immunocompromised patients with visceral leishmaniasis treated with AmBisome, relapse rates were high following initial clearance of parasites)